Fabrication of polysulphone/hydroxyapatite nanofiber composite implant and evaluation of their in vitro bioactivity and biocompatibility towards the post-surgical therapy of gastric cancer

Graphene oxide functionalized with chitosan based nanoparticles as a carrier of siRNA in regulating Bcl-2 expression on Saos-2 & MG-63 cancer cells and its inflammatory response on bone marrow derived cells from mice

“…The lower cumulative release of the siRNA at pH 7 could possibly be due to the strong interaction between the chitosan-TPP and the siRNA which was in par with the results reported by Dudhani AR et al in 2010 [28]. It was observed that the initial burst release was high with the higher concentration of siRNA than the lower concentration that was as in line with our expectations from the results of our previous studies on the effect of drug concentration on the release kinetics [22,27]. It is of these materials to relinquish the drug efficiently at acidic pH since the pH of the endosome/lysosomes would be around pH 5 [26].…”

“…At pH 7, release of siRNA complex observed to the maximum of 30-40% corresponding to the strong ionic interaction between CS and siRNA in presence of TPP. It was clear from the release mechanism that there was an increase in release of siRNA with an increase in concentration of siRNA that is in agreement with our previous study models where the use of polymer model with drug (5-FU) was analyzed [27]. The release kinetics of siRNA from graphene oxide-chitosan complex was studied at varying pH at 7, 5 and 3.…”

An update on applications of nanostructured drug delivery systems in cancer therapy: a review

“…In a study conducted by Saravanabhavan and Dharmalingam (2013), scientists concluded that PSunanofibers were successfully fabricated with the incorporation of nHA into them by using the electro spinning technique as post-surgical implants in cancer therapy. The system exhibited a high potential in delivering the anticancer drugs to the target site, and it was also demonstrated that it could be used as a postsurgical implant.…”

“…The results from the MTT assay showed that the metabolizing activity of the normal cells was not affected by the PSu; but the drug loaded composites decreased the metabolic activity of the cancerous cells. Thus, the prepared model could potentially be a carrier for anticancer drug, and it could also serve as a postsurgical implant (Ahmadi et al 2014, Ebrahimnezhad et al 2013, Mollazade et al 2013, Pourhassan-Moghaddam et al 2013, Saravanabhavan and Dharmalingam 2013, Zong et al 2015.…”

“…A combination of radiation therapy and chemotherapy is commonly applied to raise survival rates of patients. However, the absence of selectivity for tumor tissues often leads to some adverse effect for the patients who undergo a chemotherapeutic method, including kidney malfunction, nausea and vomiting, nerve injury, impairment of sight, and bone marrow suppression (Saravanabhavan andDharmalingam 2013, Zong et al 2015). Although some progress has been made in cancer therapy, there are still numerous limitations including severe toxicity in normal cells, death caused by the systematic administration of anticancer drugs at extreme endurable doses (Piccolo and Kolesar 2014), limited distribution of chemotherapy drugs from the blood vessels into the solid tumors, (Postma et al 2013) low resection rates and poor overall patient survival in surgery, (Langer 1998) and prominent clinical toxicities in radiotherapy (Minchinton and Tannock 2006).…”